HeartWorks and Mayo Clinic launch a clinical trial that involves surgically injecting lab-grown cardiac tissue—sourced from the patients’ skin cells—in people with congenital heart disease.
Learn about two innovative technologies featured in HeartWorks 101 with Dr. Matt Ames: an endovascular pump for single-ventricle patients and Heart in a Box, a system designed to support the future of congenital heart disease care.
Meet Mike Grillo, Clinical Study Manager and Monitor at HeartWorks. Learn how his work helps advance CHD research and future therapies.
HeartWorks was created to accelerate therapies for congenital heart disease by bringing research, manufacturing, and clinical care together under one mission.At HeartWorks, our regenerative medicine platform begins with something remarkably simple: a small skin biopsy.
Those cells are reprogrammed into stem cells, expanded in our manufacturing facility, and then transformed into bioengineered heart muscle cells – all using the patient’s own cells. The goal? To create therapies designed to strengthen hearts affected by congenital heart disease while minimizing the risk of immune rejection.
